Abstract:Objective: To investigate the changes in lymphocyte subsets in patients with advanced non-small-cell lung cancer (NSCLC) before and after the treatment using endostar combined with chemotherapy.Methods: Eighty-six patients with advanced NSCLC who were treated in the oncology department of our hospital from June 2018 to February 2019 were randomly selected and divided into a control group and study group using the random-number expression method, with 43 patients in each group. The control group was treated using chemotherapy (docetaxel + carboplatin). The patients in the study group were treated with endostar on the basis of the control group, and both groups were treated for 6 weeks. The clinical efficacy of the two groups was evaluated. The levels of vascular endothelial growth factor (VEGF), matrix maalloproteinase-2 (MMP2), and matrix metalloproteinase-9 (MMP-9) were measured using EL1SA. The lymphocyte subsets (CD3+, CD4+, and CD4+/CD8+) and natural killer cells (NK) were measured by flow cytometry. The adverse reactions of the two groups were compared.Results: After treatment, the objective effective rate and disease-control rate of the two groups were 65.12% and 8139%; 83.72% and 9535%, respectively, which were significantly higher in the study group than in the control group (P<0.05). After treatment, the levels of VEGF, MMP-2, and MMP-9 in the two groups were significantly lower than those before treatment, and the indexes in the study group were significantly lower (P<0.05). After treatment, the levels of NK, CD3+, CD4+, and CD4+/CD8+ in the two groups were significantly higher than those before treatment, the levels of CD8+ in the study group were significantly higher than those in the control group, and the levels of CD8+ in the study group were significantly lower than those in the control group (P<0.05). The incidence of adverse reactions was 25.58% in the study group and 48.84% in the control group. The incidences of adverse reactions in the study group were significantly lower than those in the control group (P<0.05).Conclusion: Endostar combined with chemotherapy has a significant clinical effect in the treatment of advanced NSCLC. It can reduce the levels of VEGF, MMP-2, and MMP-9 in patients with advanced NSCLC; inhibit tumour invasion and metastasis; and improve the immune function of the body in a safe and reliable manner.

Analysis on the Change of Peripheral Blood T Lymphocyte Subsets Before and after Chemotherapy in Patients with Non-Small Cell Lung Cancer

Analysis of NK/T and Treg cell in peripheral blood of patients with different malignancies during the chemotherapy

Immune Function Changes of Non-Small Cell Lung Cancer Patients after Chemotherapy

Observation of Changes in Peripheral Lymphocyte Subsets by Flow Cytometry in Patients with Non-Small Cell Lung Cancer Treated with Paclitaxel and Cisplatin

RESEARCH ON EFFECT OF CHEMOTHERAPY ON CELLULAR IMMUNITY OF PATIENTS WITH LUNG CANCER

Changes of immune pattern in lung cancer patients before and after chemotherapy

Expression of regulatory T cells in the peripheral blood and its clinical significance in patients with non-small cell lung cancer

Impact of Chemotherapy on Circulating Lymphocyte Subsets in Lung Cancer Patients

Immunomodulatory Effects of Chemotherapy on Blood Lymphocytes and Survival of Patients with Advanced Non-Small Cell Lung Cancer

Observation of Changes in Peripheral Lymphocyte Subsets by Flow Cytometry in Patients with Non-small Cell Lung Cancer with Docetaxel Combination with Cisplatin Regimen

Changes And Significance Of Lymphocyte Subsets In Patients With Advanced Nsclc Before And After Endostar Combined Chemotherapy

[Quantitative Studies on Expression of Peripheral Blood CD44 and CD54 in Non-Small Cell Lung Carcinoma].

The analysis of peripheral blood lymphocyte subgroup in patients with esophageal cancer before and after treatment

Changes of CD4+, CD8+ and B cells in peripheral blood of breast cancer patients detected before and after surgery and following chemotherapy and their clinical significance

Study on Peripheral Blood T Lymphocyte Subsets of Patients with Lung Cancer and Lung Infection

Circulating activated immune cells as a potential blood biomarkers of non-small cell lung cancer occurrence and progression

CK19 mRNA expression and its clinical significances in peripheral blood of non-small cell lung cancer patients before definitive chemoradiotherapy

[Predictive and Prognostic Value of Monitoring Lymphocyte Subsets in Peripheral Blood Before and after Chemotherapy in Patients with Metastatic Breast Cancer].

Tumor-infiltrating CD8+ and FOXP3+ Lymphocytes Before and after Neoadjuvant Chemotherapy in Cervical Cancer

Peripheral CD4+ T cells correlate with response and survival in patients with advanced non-small cell lung cancer receiving chemo-immunotherapy

Dynamic surveillance of lymphocyte subsets in patients with non-small cell lung cancer during chemotherapy or combination immunotherapy for early prediction of efficacy